zepbound semaglutide beats Wegovy for weight loss in first head-to-head study Can Zepbound Outperform Wegovy and
Description
Steqeyma hit U.S

Aquipta (atogepant) was approved by the EMA in August 2023

Understanding side effects As a class, GLP-1 analogs are known for their gastrointestinal side effects

Collectively, these sensitivity analyses support the stability and reliability of the meta-analytic findings, particularly for AHI and systolic blood pressure outcomes, reinforcing the potential of GLP-1 RAs as a therapeutic intervention in OSA

32 An analysis of US claims data from 107 patients with T2D, 56 of whom were already receiving a GLP1RA, who initiated OW semaglutide showed a 1.3%point reduction in HbA 1c in the overall population

However, this evidence is preliminary and should not be interpreted as proof of safety in all populations
